All In Biotech

Drug Trial Radar · NCT07268222

Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)

Last checked: Nov 19, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Dec 1, 2025

Primary completion

Nov 1, 2026

Study completion Nov 25, 2027

Sponsor

Lead sponsor
Laikο General Hospital, AthensAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the efficacy and safety of the two 11β-hydroxylase inhibitors-metyrapone and osilodrostat-in patients with MACS. Primary outcome To compare the efficacy (biochemical and clinical) of the two 11β-hydroxylase inhibitors (CYP11B1), metyrapone and osilodrostat, in patients with MACS not treated surgically (mainly bilateral adenomas or adrenal hyperplasias), as well as their side effects at time 0-, 3- and 6-months post-treatment. Secondary outcome To evaluate alterations in clinical parameters (Blood Pressure, Body Mass Index-BMI), metabolic parameters (fasting blood glucose, insulin, Hb1Ac, HOMA, OGTT and lipids levels) at time 0-, 3- and 6-month after the initiation of the treatment and their effect on Bone Mineral Density (BMD) 1 year post-diagnosis

Conditions

  • Mild Autonomous Cortisol Secretion (MACS)

Interventions

  • Metyrapone 250 mg Oral TabletsDrug

    metyrapone( 250 -750 mg) vs. osilodrostat (1-3 mg) vs. surgery vs watch and wait strategy in the management of patients with MACS

  • Osilodrostat 1 MGDrug

    administration of 1-3 mg of osilodrostat at 19.00

  • adrenalectomyProcedure

    Surgery performed in patients with MACS

  • Watch and waitOther

    Follow-up

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of the efficacy of metyrapone and osilodrostatTime frame: Baseline ( at t=0), at t=3 months and at =6 months
  2. Comparison of the efficacy of metyrapone and osilodristatTime frame: Baseline (at t= 0), at t= 3 months and t= 6 months
  3. Comparison of the efficacy of metyrapone and osilodristatTime frame: Baseline ( at t=0), at t=3 months and at t=6 months
  4. Comparison of the efficacy of metyrapone and osilodristatTime frame: Baseline ( at t=0), at t=3 months and at =6 months
  5. Comparison of metyrapone and osilodrostat efficacyTime frame: Baseline (at t=0), at t=3 months , at t =6 months
  6. Comparison of metyrapone and osilodrostat in terms of alterations of metabolic parametersTime frame: Baseline (t=0), at t= 3months, at t=6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laikon General Hospital

    Athens, Greece · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.